skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

We will discuss the industry trends by examining the pipeline by company, therapeutic area, disease, target and drug type, using data from Pharma Intelligence’s Phamaprojects. This report will focus on research and development as it is now, how it is changing and mutating, and where it has been headed during 2016 and will be in 2017.

 

It will be followed up by our annual supplement reviewing the New Active Substance launches for last year. 

 

Join Alex Shimmings, Executive Editor, Europe, Commercial, Scrip, Pink Sheet, In Vivo and Ian Lloyd, Senior Director, Pharmaprojects and Data Integration - Citeline as they will share insight on the following key areas:

 

  • Total pipeline size – the pharma forest is teeming with life
  • The 2017 pipeline by phase – Baby boom leads the way, but growth throughout the family
  • Top companies – Big beasts still dominate, but Novartis is the new king of the jungleTop therapies – Cancer’s herds spread further into the pharma habitat
  • Types of pipeline drugs – As biologicals proliferate, is the small molecule becoming a dinosaur?
  • Mechanisms and Targets – how to stay alive in a crowded ecosystem
  • Survival of the fittest – Darwinian forces mean pharma’s creatures must find their niches 

 

 

Read also

  • Citeline

    Citeline’s Trialtrove and Sitetrove: New Platform

    29 Jun 2017

    We've made the valuable and trustworthy content of Sitetrove and Trialtrove even better via the enhanced features of the new platform.

  • Pharmaprojects: track pharma R&D

    2018 R&D Review: 5 Key Takeaways

    Welcome to Pharmaprojects’ roundup of key trends in pharmaceutical R&D in 2018, focusing on five key takeaways from our full annual report

  • Citeline

    Clinical Trials Industry Report

    Clinical trials are continually evolving, particularly in light of increasing pressures from new technologies and other disruptors. Trends ranging from artificial intelligence (AI) and mHealth to patient-centricity are challenging the industry to innovate against the backdrop of looming regulatory changes and shifting competitor landscapes resulting from M&A activity. In order to explore these trends, KNect365 Life Sciences recently conducted one of the biggest surveys of its kind across clinical trial professionals from within pharma, CROs, sites, service providers, academia and patient groups across the world to look beyond the hype.

    Topics Clinical trials Clinical trial optimization

;

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: